氯吡格雷预防冠心病介入治疗后心血管不良事件发生的临床效果(1)
[摘要]目的 探究冠心病介入治疗后采用氯吡格雷对心血管不良事件发生的预防效果。方法 选取2015年7月～2017年1月我院收治的84例接受介入治疗的冠心病患者作为研究对象，根据双盲法分为两组，每组各42例。对照组患者予以低分子肝素治疗，观察组患者予以氯吡格雷治疗，并对两组患者的活化部分凝血活酶时间、凝血酶时间、凝血酶原时间以及纤维蛋白原、用药后血栓素B2水平、心血管不良事件發生率以及治疗满意度进行对比。结果 两组患者的活化部分凝血活酶时间、凝血酶时间、凝血酶原时间以及纤维蛋白原方面比较，差异均无统计学意义(P>0.05)；用药后6、12 h及1 d，观察组患者的血栓素B2水平分别为(82.22±14.85)ng/L、(65.13±12.52)ng/L及(46.70±9.12)ng/L，均低于对照组的(93.15±16.49)ng/L、(75.42±15.01)ng/L及(66.91±11.04)ng/L，差异有统计学意义(P<0.05)；观察组患者的心血管不良事件发生率(4.76%)低于对照组(26.18%)，差异有统计学意义(P<0.05)。观察组患者的治疗满意度(97.62%)高于对照组(78.57%)，差异有统计学意义(P<0.05)。结论 冠心病介入治疗后采用氯吡格雷对心血管不良事件发生的预防效果显著。
[关键词]氯吡格雷；冠心病；介入治疗；心血管不良事件；临床效果
[中图分类号] R544.1 [文献标识码] A [文章编号] 1674-4721(2018)9(a)-0075-03
[Abstract] Objective To explore the preventive effect of clopidogrel on adverse cardiovascular events (ACEs) after interventional treatment of coronary heart disease (CHD). Methods Eighty-four CHD patients admitted to our hospital from July 2015 to January 2017 were selected as the subjects， and divided into two groups according to the double-blinding， with 42 cases in each group. In control group， patients were treated with low molecular weight heparin， while in observation group， clopidogrel was provided. The activated partial thromboplastin time， thrombin time， prothrombin and fibrinogen time， post-treatment thromboxane B2 level， incidence of ACEs， and treatment satisfaction were compared between the two groups. Results There was no significant difference in activated partial thromboplastin time， thrombin time，prothrombin or fibrinogen time between the two groups (P>0.05). After 6， 12 and 24-hour treatment， the thromboxane B2 levels in the observation group were (82.22±14.85) ng/L， (65.13±12.52) ng/L， and (46.70±9.12) ng/L respectively， all lower than those in the control group for (93.15±16.49) ng/L， (75.42±15.01) ng/L and (66.91±11.04) ng/L (P<0.05). The incidence of ACEs in the observation group was 4.76%， which was lower than that in the control group accounting for 26.18%， with a significant difference (P<0.05). The treatment satisfaction from patients in the observation group was 97.62%， higher than that in the control group accounting for 78.57%， with statistical significance (P<0.05). Conclusion The use of clopidogrel in interventional treatment of CHD has a significant effect on the prevention of ACEs.
[Key words] Clopidogrel； Coronary heart disease； Interventional therapy； Adverse cardiovascular events； Clinical effect
冠心病在临床上属于一种常见的心血管疾病，最近几年的发病率越来越高，对患者的生活质量有直接影响。临床上通常采用冠状动脉介入手术治疗，但术后会常常有血栓产生，引发心血管不良事件出现，为患者的恢复带来不利影响[1]。因此预防冠心病介入治疗后心血管不良事件的出现，对于确保临床效果与改善预后十分必要。临床上通常采用抗血小板聚集药物治疗，但不同药物的治疗效果也存在差异[2]。氯吡格雷能够对血小板的聚集产生抑制作用，将形成的血小板血栓有效消除，并消除含大量纤维蛋白的红素血栓[3]。多数研究显示：氯吡格雷在冠心病介入治疗后应用，可使患者的不良事件发生率有效降低，提高患者的治疗效果[4]。为了探究冠心病介入治疗后采用氯吡格雷对心血管不良事件发生的预防效果，本研究选取84例接受介入治疗的冠心病患者作为研究对象，对患者的治疗效果与心血管不良事件发生率予以比较，现报道如下。, 百拇医药(王单)
[关键词]氯吡格雷；冠心病；介入治疗；心血管不良事件；临床效果
[中图分类号] R544.1 [文献标识码] A [文章编号] 1674-4721(2018)9(a)-0075-03
[Abstract] Objective To explore the preventive effect of clopidogrel on adverse cardiovascular events (ACEs) after interventional treatment of coronary heart disease (CHD). Methods Eighty-four CHD patients admitted to our hospital from July 2015 to January 2017 were selected as the subjects， and divided into two groups according to the double-blinding， with 42 cases in each group. In control group， patients were treated with low molecular weight heparin， while in observation group， clopidogrel was provided. The activated partial thromboplastin time， thrombin time， prothrombin and fibrinogen time， post-treatment thromboxane B2 level， incidence of ACEs， and treatment satisfaction were compared between the two groups. Results There was no significant difference in activated partial thromboplastin time， thrombin time，prothrombin or fibrinogen time between the two groups (P>0.05). After 6， 12 and 24-hour treatment， the thromboxane B2 levels in the observation group were (82.22±14.85) ng/L， (65.13±12.52) ng/L， and (46.70±9.12) ng/L respectively， all lower than those in the control group for (93.15±16.49) ng/L， (75.42±15.01) ng/L and (66.91±11.04) ng/L (P<0.05). The incidence of ACEs in the observation group was 4.76%， which was lower than that in the control group accounting for 26.18%， with a significant difference (P<0.05). The treatment satisfaction from patients in the observation group was 97.62%， higher than that in the control group accounting for 78.57%， with statistical significance (P<0.05). Conclusion The use of clopidogrel in interventional treatment of CHD has a significant effect on the prevention of ACEs.
[Key words] Clopidogrel； Coronary heart disease； Interventional therapy； Adverse cardiovascular events； Clinical effect
冠心病在临床上属于一种常见的心血管疾病，最近几年的发病率越来越高，对患者的生活质量有直接影响。临床上通常采用冠状动脉介入手术治疗，但术后会常常有血栓产生，引发心血管不良事件出现，为患者的恢复带来不利影响[1]。因此预防冠心病介入治疗后心血管不良事件的出现，对于确保临床效果与改善预后十分必要。临床上通常采用抗血小板聚集药物治疗，但不同药物的治疗效果也存在差异[2]。氯吡格雷能够对血小板的聚集产生抑制作用，将形成的血小板血栓有效消除，并消除含大量纤维蛋白的红素血栓[3]。多数研究显示：氯吡格雷在冠心病介入治疗后应用，可使患者的不良事件发生率有效降低，提高患者的治疗效果[4]。为了探究冠心病介入治疗后采用氯吡格雷对心血管不良事件发生的预防效果，本研究选取84例接受介入治疗的冠心病患者作为研究对象，对患者的治疗效果与心血管不良事件发生率予以比较，现报道如下。, 百拇医药(王单)